About Alumis
Alumis is a publicly listed company based in San Francisco (United States) founded in 2003. It operates as a therapeutics for autoimmune diseases are developed by Alumis. Alumis has raised $529 million across 5 funding rounds from investors including General Atlantic, Piper Sandler and HBM Healthcare Investments. The company has 168 employees. Its chief executive is Martin Babler. Its website alumis.com draws about 22 thousand monthly visits. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its competitors include Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Alumis was founded in 2003 and is based in San Francisco, United States. Focus is placed on the development of therapeutics targeting autoimmune diseases within the biotechnology sector. Operations involve research into inhibitors like the lead candidate SK-001, a TYK2 pseudokinase allosteric inhibitor for psoriasis. The TYK2 gene is recognized for encoding a tyrosine kinase that mediates inflammation and autoimmune responses.
- Headquarters San Francisco, United States
- Employees 168
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website alumis.com
- Social LinkedIn X
- Legal Name Alumis Inc.
- Annual Revenue$24.05 M (USD)0as on Dec 31, 2025
- Net Profit-$243.32 M (USD)17.3as on Dec 31, 2025
- EBITDA-$423.71 M (USD)-42.37as on Dec 31, 2025
- Total Equity Funding$529M (USD)
in 5 rounds
- Latest Funding Round$40M (USD), Post-IPO
Jul 2024
- InvestorsGeneral Atlantic
& 13 more
- Employee Count168
Funding Insights of Alumis
Alumis has successfully raised a total of $529M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $529M
- Total Rounds 5
- Last Round Post-IPO — $40M
- First Round $70M
(May 2021)
- Investors Count 14
All 5 funding rounds of Alumis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $40M | Post-IPO | – | – | – |
| Mar 2024 | $259M | Series C | – | Foresite Capital, Samsara BioCapital | |
| Jun 2023 | – | Series B | – | General Atlantic | – |
| Jan 2022 | $200M | Series B | – | – | |
| May 2021 | $70M | Series A | – | Foresite Capital | – |
14 investors in total: 14 institutional.
Investors in Alumis
Alumis has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include General Atlantic, Piper Sandler and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Venture capital funding is provided by Samsara BioCapital in California. | – | samsaracap.com | Palo Alto, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Healthcare startups are funded by this venture capital firm. | – | cormorantassetmanagement.tcc.mode | Ponte Vedra, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
- | – | nextechventure.com | - | |
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Venture capital firm | – | omegafunds.com | Boston, United States | |
Private equity fund focused on global markets | 1980 | generalatlantic.com | New York, United States |
Investor details for Alumis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alumis
69 people are tracked at Alumis (56 in leadership, 13 in team); the tracked headcount is 168.
| Name | Role | Group |
|---|---|---|
Martin Babler | CEO | Leadership |
Dean Dragoli | Vice President, Medicinal Chemistry | Leadership |
Mekhala Maiti | Director, Biology | Leadership |
Eric Ingalla | Senior Director Regulation Affairs CMC | Leadership |
Susan Owen | Vice President, Head Of Clinical Operations | Leadership |
Shella Edejer | Associate Director | Leadership |
Milly Kitty Toor | Executive Director And Project Team Leader | Leadership |
Lily Gong | Executive Director And Head Of Regulatory Strategy | Leadership |
Grace Halteh | Senior Vice President, Quality And Regulatory | Leadership |
Ruixiao Lu | Vp, Head Of Biostatistics And Statistical Programming | Leadership |
Michael Gameng | Director, R&d Business Partner | Leadership |
David M Goldstein | Chief Scientific Officer | Leadership |
David Alonzo | Vice President, Drug Product Development | Leadership |
Philip Nunn | Senior Vice President Preclinical Development Alumis INC | Leadership |
Sara Han | Director, Drug Product Development | Leadership |
Kareem Graham | Director, Biology | Leadership |
Linda Chan-Kim | Director, Development Systems & Business Informatics | Leadership |
Tim Owens | Svp, Head Of Research | Leadership |
Jingrong Xu | Director Drug Product Development | Leadership |
Penny Blensdorf | Associate Director, Legal Operations & Corporate Paralegal | Leadership |
49 more people are available in the full profile.
Complete people profiles for Alumis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alumis
Alumis is a publicly listed company on the NASDAQ with ticker symbol ALMS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Jun 2024
- Listed onNYSE: ALMS
- Listed entityAlumis Inc.
- Exchange sectorHealth technology
- ISINUS0223071020
- Share price$6.56 (-7.08% on the day) · 2026-10-13
- Market capitalisation$875.7M
- EPS (diluted, trailing year)$-3.81
- Volume (last session)1,899,431
Financials of Alumis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $24.1M | -$243.3M | -$423.7M |
| 2024 | – | -$294.2M | -$297.6M |
| 2023 | – | -$155.0M | -$156.9M |
| 2022 | – | -$111.9M | -$113.6M |
Detailed financial statements for Alumis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Alumis
4 dated milestones of Alumis across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Alumis is founded.
- Funding First funding round of $70.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $40.0M.
Competitors of Alumis
Alumis has 9 listed competitors in our database, 9 of them funded. They include Moderna, Forge Biologics, Aclaris Therapeutics, Annexon and Ventyx Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | – | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| cogentbio.com | 2014 | Cambridge, United States | $77M | 164 | Precision therapies for genetically defined diseases are developed. |
Detailed competitors of Alumis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alumis
The website of Alumis (alumis.com) receives about 22.2K visits a month and ranks #2,196,103 among all websites worldwide, #2,982 in Biotechnology and Pharmaceuticals.
- Monthly visits22.2K
▲ 131.6% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,196,103
among all websites
- Category rank#2,982
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.0
- Average visit18 sec
- DevicesDesktop 53% · Mobile 47%
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Alumis (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alumis
Complete news archive for Alumis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alumis
Alumis was founded in 2003 and raised its 1st funding round 18 years after it was founded.
Alumis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Martin Babler is the current CEO of Alumis.
Alumis is a funded company, having raised a total of $529M across 5 funding rounds to date. The company's 1st funding round was a Series A of $70M, raised on May 2021.
Alumis has 168 employees.
Annual revenue of Alumis is $24.05M as on Dec 31, 2025.
Alumis was founded in 2003 and is based in San Francisco, United States. Focus is placed on the development of therapeutics targeting autoimmune diseases within the biotechnology sector. Operations involve research into inhibitors like the lead candidate SK-001, a TYK2 pseudokinase allosteric inhibitor for psoriasis. The TYK2 gene is recognized for encoding a tyrosine kinase that mediates inflammation and autoimmune responses.
Alumis's top competitors include Moderna, Forge Biologics and Annexon.
Yes, Alumis is publicly traded on NASDAQ under the ticker symbol ALMS.
Alumis has 14 investors. Key investors include General Atlantic, Piper Sandler, HBM Healthcare Investments, AyurMaya, and Foresite Capital.